Drugs / Darigabat
Darigabat
Trials 17 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 111 trials | ||||||
| Phase 1 | NCT06435923 | May → Jul 2024 | — | Cerevel Therapeutics, LLC | Completed | No outcome recorded |
| Phase 1 | NCT05824143 | Apr → Jul 2023 | — | Cerevel Therapeutics, LLC | Completed | No outcome recorded |
| Phase 1 | NCT05123079 | Nov 2021 | — | Cerevel Therapeutics, LLC | Completed | No outcome recorded |
| Phase 1 | NCT04592536 | Oct 2020 → Nov 2021 | panic disorder | Cerevel Therapeutics, LLC | Completed | No outcome recorded |
| Phase 1 | NCT03351751 | Nov 2017 → Feb 2018 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT02475746 | Jul → Aug 2015 | — | Pfizer | Withdrawn | No outcome recorded |
| Phase 1 | NCT02238717 | Sep → Nov 2014 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT02217787 | Sep 2014 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT02138500 | May → Aug 2014 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT02070289 | Mar → Jul 2014 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT01951144 | Oct 2013 → Jul 2014 | — | Pfizer | Completed | No outcome recorded |
| Phase 26 trials | ||||||
| Phase 2 | NCT05941442 | Jul 2023 → Mar 2025 | panic disorder | AbbVie | Terminated | No outcome recorded |
| Phase 2 | NCT04686786 | Dec 2020 → Dec 2024 | epilepsy | AbbVie | Terminated | No outcome recorded |
| Phase 2 | NCT04244175 | Jan 2020 → May 2024 | epilepsy | AbbVie | Completed | No outcome recorded |
| Phase 2 | NCT02564029 | Dec 2015 → Jan 2017 | photosensitive epilepsy | Pfizer | Completed | No outcome recorded |
| Phase 2 | NCT02310568 | Nov 2014 → Oct 2015 | generalized anxiety disorder | Pfizer | Terminated | No outcome recorded |
| Phase 2 | NCT02262754 | Oct 2014 → Aug 2015 | chronic pain syndrome | Pfizer | Completed | No outcome recorded |
Press releases naming this drug 5 releases
| Date | Issuer | Release |
|---|---|---|
| 2022-02-15 | AbbVie | Cerevel Therapeutics Announces Positive Topline Results for Darigabat in Phase 1 Clinical Trial in Acute Anxiety abbvie.com ↗ |
| 2021-01-28 | AbbVie | Cerevel Therapeutics Hosts Inaugural Virtual R&D Event to Review Darigabat (CVL-865) and Provide Overview of Key Preclinical Programs abbvie.com ↗ |
| 2020-10-06 | AbbVie | Cerevel Therapeutics Announces First Patient Dosed in Phase 2 Trial of CVL-865, an Investigational Therapy in Development for the Treatment of Epilepsy abbvie.com ↗ |
| 2019-12-08 | AbbVie | Cerevel Therapeutics Announces Phase 1 Results for CVL-865, a Novel α2/3/5-subtype GABAA Positive Allosteric Modulator in Development to Treat Epilepsy abbvie.com ↗ |
| 2019-11-25 | AbbVie | Cerevel Therapeutics to Present Safety, Tolerability, and Pharmacokinetics Results from Phase 1 Trial of CVL-865 abbvie.com ↗ |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 18 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Darigabat | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05123079 ↗ |
| Known as | CVL-865 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04592536 ↗ |
| Known as | PF-06372865 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02238717 ↗ |
| Modality | Small molecule | — CHEMBL3647536 ↗ |
| Route | Oral | “single oral doses of PF-06372865” NCT01951144 ↗ |